Dr. Dana P. Ascherman, MD

Dr. Ascherman practices at Pittsburgh VAMC in Pittsburgh, Pennsylvania.

Dr. Ascherman's NPI, 1720050123, was assigned on February 2, 2006. Dr. Ascherman graduated from Stanford University School Of Medicine in 1992. Dr. Ascherman's Florida license number on file is ME 108262.

Dr. Ascherman's primary practice is Pittsburgh VAMC, at 4100 Allequippa St, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 688-6322.

Dr. Ascherman's primary practice is Pittsburgh VAMC in Pittsburgh, Pennsylvania. Dr. Ascherman is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Ascherman to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ascherman practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Ascherman's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Ascherman is board certified in rheumatology by the American Board of Internal Medicine. Dmand AI has Dr. Ascherman's licenses on file in 3 states: Florida, Pennsylvania and District of Columbia.

Dmand AI lists arteritis, arthritis, gout, joint pain, muscle pain, fibromyalgia, and limb pain and rheumatoid arthritis among the conditions Dr. Ascherman treats.

CMS data shows 68 Medicare services from Dr. Ascherman across 2 procedure codes in 2024, for 67 Medicare patients. Medicare paid $3,582 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 67 Medicare patients who saw Dr. Ascherman in 2024. The largest group is 65 to 74, with 34 patients. 75% of them have arthritis, and 75% have high cholesterol. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ascherman's median patient age at 69, with 57% women.

In 2024, Dr. Ascherman wrote 871 Medicare Part D claims for 107 patients. 78% of them were for generic drugs. CMS names the drug for 743 of them, across 23 drugs with 11 or more claims each, at $645,869 in total drug cost. In 2023, CMS named 751 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Ascherman for performance year 2024, reported as part of a group. Dr. Ascherman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ascherman as offering telehealth.

Dmand AI links 71 papers to Dr. Ascherman, published from 2008 to 2025. 2024 was the busiest year, with 8. The most frequent topics are Lung Diseases, Interstitial, Arthritis, Rheumatoid and Autoantibodies. Dr. Ascherman has published most often in Arthritis Rheumatol. Dr. Ascherman's most frequent co-authors are Rohit Aggarwal, MD, Ted R. Mikuls, MD and Gail S. Kerr, MD.

CMS Open Payments shows 36 general payments to Dr. Ascherman from 8 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 74% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $9,971.

Dmand AI lists 2 awards for Dr. Ascherman, most recently ACR Fellow in 2013.

Dr. Ascherman graduated from Stanford University School Of Medicine in 1992. Dr. Ascherman is a member of ACR.

Dr. Ascherman is in network with 12 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Highmark. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.